相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
Catherine de Martel et al.
LANCET ONCOLOGY (2012)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen et al.
LANCET ONCOLOGY (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
200 NEJM ANNIVERSARY ARTICLE The Perpetual Challenge of Infectious Diseases
Anthony S. Fauci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Efficacy Results of a Trial of a Herpes Simplex Vaccine
Robert B. Belshe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HIV vaccine development at the turn of the 21st century
Marc P. Girard et al.
CURRENT OPINION IN HIV AND AIDS (2012)
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up
Cecilia M. Roteli-Martins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
Elmar A. Joura et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Developments in virus-like particle-based vaccines for infectious diseases and cancer
Luigi Buonaguro et al.
EXPERT REVIEW OF VACCINES (2011)
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2011)
Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges
Morgane Bomsel et al.
IMMUNITY (2011)
HSV-2: in pursuit of a vaccine
Christine Johnston et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual Couples
Ann N. Burchell et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease
Anil K. Chaturvedi et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection
Stephanie Longet et al.
JOURNAL OF VIROLOGY (2011)
Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study
Julia M. L. Brotherton et al.
LANCET (2011)
Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data
Basil Donovan et al.
LANCET INFECTIOUS DISEASES (2011)
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2011)
Primary human epithelial cell culture system for studying interactions between female upper genital tract and sexually transmitted viruses, HSV-2 and HIV-1
Charu Kaushic et al.
METHODS (2011)
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Joel M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection
Zili Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
Troy J. Kemp et al.
VACCINE (2011)
Herpes simplex virus infects most cell types in vitro: clues to its success
Ghadah A. Karasneh et al.
VIROLOGY JOURNAL (2011)
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Rolando Herrero et al.
CANCER DISCOVERY (2011)
The Role of Antibodies in HIV Vaccines
John R. Mascola et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection
Patricia M. Day et al.
CELL HOST & MICROBE (2010)
Mechanisms that determine plasma cell lifespan and the duration of humoral immunity
Ian J. Amanna et al.
IMMUNOLOGICAL REVIEWS (2010)
Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design
Jiri Mestecky et al.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2010)
Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence
Susanne K. Kjaer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
Nubia Munoz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Hans-Ulrich Bernard et al.
VIROLOGY (2010)
Strategies for eliciting HIV-1 inhibitory antibodies
Georgia D. Tomaras et al.
CURRENT OPINION IN HIV AND AIDS (2010)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Susanne K. Kjaer et al.
CANCER PREVENTION RESEARCH (2009)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10-18 Years
Tiina Petaja et al.
JOURNAL OF ADOLESCENT HEALTH (2009)
Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine
Suzanne M. Garland et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable Regions
Ralph Pantophlet et al.
JOURNAL OF VIROLOGY (2009)
Human Immunodeficiency Virus Type 1 Is Trapped by Acidic but Not by Neutralized Human Cervicovaginal Mucus
Samuel K. Lai et al.
JOURNAL OF VIROLOGY (2009)
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
B. Romanowski et al.
LANCET (2009)
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding
Rhonda C. Kines et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine
Sita Awasthi et al.
VACCINE (2009)
Oncogenic activities of human papillomaviruses
Margaret E. McLaughlin-Drubin et al.
VIRUS RESEARCH (2009)
HIV infection of the genital mucosa in women
Florian Hladik et al.
Current HIV/AIDS Reports (2009)
Coming of age of virus-like particle vaccines
Gary T. Jennings et al.
BIOLOGICAL CHEMISTRY (2008)
Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E
Lauren M. Hook et al.
JOURNAL OF VIROLOGY (2008)
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis
Kimberly A. Powers et al.
LANCET INFECTIOUS DISEASES (2008)
Identification and characterisation of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
Elmar A. Joura et al.
VACCINE (2008)
Duration of humoral immunity to common viral and vaccine antigens
Ian J. Amanna et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
Jeffrey N. Roberts et al.
NATURE MEDICINE (2007)
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion
Martyn Plummer et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like pailicle vaccine containing AS04 adjuvant
Court Pedersen et al.
JOURNAL OF ADOLESCENT HEALTH (2007)
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
Stan L. Block et al.
PEDIATRICS (2006)
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Sandra L. Giannini et al.
VACCINE (2006)
Distribution and three-dimensional structure of AIDS virus envelope spikes
Ping Zhu et al.
NATURE (2006)
The global health burden of infection -associated cancers in the year 2002
Donald Maxwell Parkin
INTERNATIONAL JOURNAL OF CANCER (2006)
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera
Joseph J. Carter et al.
JOURNAL OF VIROLOGY (2006)
Genome variation of human papillomavirus types: Phylogenetic and medical implications
HU Bernard et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells
P Lenz et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
DV Pastrana et al.
VIROLOGY (2004)
The cervical cancer epidemic that screening has prevented in the UK
J Peto et al.
LANCET (2004)
Efficient intracellular assembly of papillomaviral vectors
CB Buck et al.
JOURNAL OF VIROLOGY (2004)
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles
D Nardelli-Haefliger et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques
TW Tobery et al.
VACCINE (2003)
Antibody neutralization and escape by HIV-1
XP Wei et al.
NATURE (2003)
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells
P Lenz et al.
CLINICAL IMMUNOLOGY (2003)
Epidemiologic classification of human papillomavirus types associated with cervical cancer
N Muñoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles
B Chackerian et al.
JOURNAL OF IMMUNOLOGY (2002)
Glycoprotein-D-adjuvant vaccine to prevent genital herpes
LR Stanberry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Secretory component:: A new role in secretory IgA-mediated immune exclusion in vivo
A Phalipon et al.
IMMUNITY (2002)
The causal relation between human papillomavirus and cervical cancer
FX Bosch et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
CD Harro et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
NHPV16VLP vaccine induces human antibodies that neutralize divergent variants of HPV16
DV Pastrana et al.
VIROLOGY (2001)
A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types
KL Liaw et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection
JJ Carter et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
JR Mascola et al.
NATURE MEDICINE (2000)
分享论文
